高脂血症中医“血脉微型癥瘕”论及其软坚散结法方药的研究
|
摘要
目的：宗转化医学理念,本“涤其体而达其用”的思想,在“血脉微型癥瘕”概念提出的基础上立软坚散结,消积去腐法拟以新疆地产药物阿魏为君药的中药处方,并基于现代理论技术,通过拟临床及临床研究评价中医药治疗高脂血症的有效性及安全性,以此证明：1)理论创新是提升中医临床疗效的关键所在；2)转化医学模式对中医学的发展具有积极的指导意义。方法：1)在对中医古今文献中高脂血症的病因病机辨证分型以及临床试验进行系统评价。2)通过建立动物病证模型进行拟临床研究。3)通过多中心、随机、双盲、安慰剂平行对照设计的临床研究,确定软坚散结消积去腐法治疗高脂血症的有效性和安全性。结果：1)6054例高脂血症病例调研结果显示：痰瘀互结、痰湿(浊)内阻、脾虚湿盛为主要证型,占57.46%。RCT临床研究显示：中药治疗高脂血症血脂疗效平均有效率为76.86%。TG平均降低0.83±0.49mmol/L。未见中药治疗导致肝肾功能异常的病例报道。2)建立了阿魏胶囊的指纹图谱；阿魏胶囊降低正常和高脂血症动物TC、TG、LDLC,升高HDLC(P<0.05或P<0.01),并能预防高脂饮食动物血脂异常。连续给药6月,高剂量组脾功能亢进,RBC、HGB、HCT下降,停药1月后恢复。体外细胞毒试验结果显示：药物作用后,细胞增殖。3)临床研究结果显示,血脂疗效平均有效率为74.50%,中医证侯疗效有效率为79.19%。中药组服药前后TC、TG、HDL-C、LDL-C差异均有统计学意义(P<0.05或P<0.01),TG下降0.8503±1.803mmol/L。结论：1)从“涤其体而达其用”的思想出发提出“血脉微型癥瘕”学说立软坚散结、消积祛腐法在高脂血症的治疗中独辟蹊径,并在此基础上研制的阿魏胶囊治疗高脂血症安全有效,且质量可控。说明理论创新是促进中医药发展的核心。2)拟临床及临床研究结果均显示阿魏胶囊具有调节血脂作用,其中降低TG作用尤为明显。3)基于中医理论创新及创新理论指导下的理法方药,借助现代技术和方法进行研究和评价,得出末端指标明确,安全、有效、质量可控的现代复方中药制剂。以此证明,转化医学模式对中医临床水平的提升具有积极的指导意义。
Aim:Apply the translational medicine principles and methods, based on "ignore the nature of a drug and to emphasize on drug usage" thought, accordance to "Blood vessel midget mass" conception propose softening hardness and dissipating mass, esolving accumulation and eliminating pus and necrotic tissues, cooling blood to remove apthogenic heat method and use Chinese medicine prescription contain Ferula asafoetida L as a principal drug for treatment hyperlipoidemia, also applied clinical-mimetic research and clinical research to evaluation the Chinese medicine efficacy and safety on treating on hyperlipoidemia. 1)Theory innovation is is crucial to promote the Chinese medicine curative effect.2) Prove translational medicine model has prevalent meaning of guidance to Chinese medicine development. Method:1) The pathogeny, pathogenesis and differentiation of symptoms and signs for classification of syndrome on hyperlipoidemia of the traditional Chinese medicine dynasties literature were systematically evaluated.2) Establish diseases animal model conduct the clinical-mimetic research.3) A Multi-center, Randomized, Double-blind, Placebo-controlled, Clinical Trial was adopted to evaluation the efficacy and safety of Ruanjiansanjie (softening hardness and dissipating mass) therapy method treating for hyperlipoidemia. Results:1) 6054 cases of hyperlipoidemia were selected for this study, the results showed that: Intermingled Phlegm and Blood Stasis, Resistance within the sputum wet muddy, Spleen Dysfunction due to Dampness is main syndrome, account for 57.46%. the clinical trial results showed that the total efficacy of Chinese medicine treatment for hyperlipoi-demia was 76.86%Decrease the TG average 0.83±0.49mmol/L。did not found adverse effect to main organ such as liver and kidney.2) a fingerprinting map of Ferula asafoetida L was also made, Ferula asafoetida L can decrease the normal rat and hyperlipoidemia animal model TC TG、LDLC, increase HDLC (P<0.05), and prevent high fat diet cause abnormity of plasma lipid. Administrate for six month period the high dosage group has hypersplenia, RBC、HGB、HCTdecresing, but recover after discontinuation of medicine。cytotoxicity test results showed that the medicice induce cell proliferation.3) clinical trial results showed that the average efficacy was 74.50%, the Chinese syndrome effecay was 79.19%O there was significantly different between those in the pre-and post-treatment TC、TG、HDL-C、LDL-C (P<0.05 or P<0.01) in chinese medicine treatment group, TG was decreased at 0.8503±1.803mmol/L. Conclusion:1) Based on "ignore the nature of a drug and to emphasize on drug usage" thought, "Blood vessel midget mass" theory san support the softening hardness and dissipating mass, esolving accumulation and eliminating pus and necrotic tissues, cooling blood to remove apthogenic heat method for hyperlipoidemia and open a new road for Chinese treatment for hyperlipoidemia. Additionally the new Chinese medicine "Awei capsule " was developed according the theory for treatment hyperlipoidemia, the medicine has safety, effecay, quality controllable. This results can explain theory innovation is core of Chinese medicine development.2) clinical-mimetic research and clinical research results showed that "Awei capsule" has lipid regulation effection, among them remarkedly decerease TG.3) based on Chinese medicine theory innovation and innovation theory guide to Chinese prescription, also apply modern techniques and method to research and evaluate Chinese prescription, can develop safety, effective, quality controllable modern Chinese medicine. The study is not only of important theory value, but also translational medicine positive reality meaning to improve the Chinese medicine,
Aim:Apply the translational medicine principles and methods, based on "ignore the nature of a drug and to emphasize on drug usage" thought, accordance to "Blood vessel midget mass" conception propose softening hardness and dissipating mass, esolving accumulation and eliminating pus and necrotic tissues, cooling blood to remove apthogenic heat method and use Chinese medicine prescription contain Ferula asafoetida L as a principal drug for treatment hyperlipoidemia, also applied clinical-mimetic research and clinical research to evaluation the Chinese medicine efficacy and safety on treating on hyperlipoidemia. 1)Theory innovation is is crucial to promote the Chinese medicine curative effect.2) Prove translational medicine model has prevalent meaning of guidance to Chinese medicine development. Method:1) The pathogeny, pathogenesis and differentiation of symptoms and signs for classification of syndrome on hyperlipoidemia of the traditional Chinese medicine dynasties literature were systematically evaluated.2) Establish diseases animal model conduct the clinical-mimetic research.3) A Multi-center, Randomized, Double-blind, Placebo-controlled, Clinical Trial was adopted to evaluation the efficacy and safety of Ruanjiansanjie (softening hardness and dissipating mass) therapy method treating for hyperlipoidemia. Results:1) 6054 cases of hyperlipoidemia were selected for this study, the results showed that: Intermingled Phlegm and Blood Stasis, Resistance within the sputum wet muddy, Spleen Dysfunction due to Dampness is main syndrome, account for 57.46%. the clinical trial results showed that the total efficacy of Chinese medicine treatment for hyperlipoi-demia was 76.86%Decrease the TG average 0.83±0.49mmol/L。did not found adverse effect to main organ such as liver and kidney.2) a fingerprinting map of Ferula asafoetida L was also made, Ferula asafoetida L can decrease the normal rat and hyperlipoidemia animal model TC TG、LDLC, increase HDLC (P<0.05), and prevent high fat diet cause abnormity of plasma lipid. Administrate for six month period the high dosage group has hypersplenia, RBC、HGB、HCTdecresing, but recover after discontinuation of medicine。cytotoxicity test results showed that the medicice induce cell proliferation.3) clinical trial results showed that the average efficacy was 74.50%, the Chinese syndrome effecay was 79.19%O there was significantly different between those in the pre-and post-treatment TC、TG、HDL-C、LDL-C (P<0.05 or P<0.01) in chinese medicine treatment group, TG was decreased at 0.8503±1.803mmol/L. Conclusion:1) Based on "ignore the nature of a drug and to emphasize on drug usage" thought, "Blood vessel midget mass" theory san support the softening hardness and dissipating mass, esolving accumulation and eliminating pus and necrotic tissues, cooling blood to remove apthogenic heat method for hyperlipoidemia and open a new road for Chinese treatment for hyperlipoidemia. Additionally the new Chinese medicine "Awei capsule " was developed according the theory for treatment hyperlipoidemia, the medicine has safety, effecay, quality controllable. This results can explain theory innovation is core of Chinese medicine development.2) clinical-mimetic research and clinical research results showed that "Awei capsule" has lipid regulation effection, among them remarkedly decerease TG.3) based on Chinese medicine theory innovation and innovation theory guide to Chinese prescription, also apply modern techniques and method to research and evaluate Chinese prescription, can develop safety, effective, quality controllable modern Chinese medicine. The study is not only of important theory value, but also translational medicine positive reality meaning to improve the Chinese medicine,
引文
[1]赵文华,张坚,由悦,等.中国18岁及以上人群血脂异常流行特点研究.中华预防医学杂志,2005,39(5)：360-310
[2]王新陆·脑血辨证[M].北京：中国医药科技出版社,2002：82-99
[3]韩淑亚,张笑峥.高脂血症病因病机研究进展[J].甘肃中医,2001,14(3)：88-90
[4]王宪波.中西医治疗冠心病[M].北京：中国中医药出版社,1995：206-207
[5]刘进,常建军,刘侃,等.降脂口服液治疗原发性高脂血症疗效观察[J].中医研究,1993,6(2)：22.
[6]孙丽英,焦亚斌,康广盛.高脂血证的病因病机研究进展[J].中医药学报,2004,32(2)：70-71
[7]钱卫东,钱小奇.高脂血证中医论治法则探讨[J].陕西中医,2002,22(8)：712-713.
[8]佟丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244
[9]中华医典·4方书类·4.1综合方书·4.12宋元方书·仁斋直指方论(附补遗)·卷之七·痰涎·附诸方
[10]王中琳,王新陆.从“血浊”辨治高脂血症经验[J].山东中医药大学学报,2007,31(6)：474-475.
[11]张玉珍.中医妇科学[M].北京：人民卫生出版社,2001：122.
[12]卓鹏伟,吴鸿洲.浅析叶天士瘕证治[J].中国中医急症,2010,19(7)：1171.
[13]中华医典·1.医经类·1.1灵枢·1.31注释·黄帝内经灵枢集注·卷五·逆顺肥瘦第三十八
[14]中华医典·3本草类·3.1综合本草·3.13明代本草·本草纲目·主治第三卷·百病主治药·下血
[15]卓鹏伟,吴鸿洲.浅析叶天士瘕证治[J].中国中医急症,2010,19(7)：1204.
[16]中华医典·本草类·综合本草·玉楸药解·卷二·木部
[17]中华医典·3本草类·3.1综合本草·3.13明代本草·神农本草经疏·卷十一·草部下品之下·山慈菇
[18]中华医典·3本草类·3.1综合本草·3.14清代本草·本草新编·卷之四(徵集)·山慈菇根
[19]祝世讷.转化生效—中药的复杂功效机制[J].2008,32(3)：179.
[20]Marineola FM. Translational medicine:a two-way road[J]. J Transl Med,2003, 1(1):1.
[21]蒋跃绒,陈可冀.转化医学与中西医结合的研究和发展[J].中国中西医结合杂 志,2010,30(10)：1017-1020.
[22]Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials:Is blinding necessary? Control Clin Trials 1996,17:1-12.
[23]Moher D, Pham B, Jones A et al. Dose quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet,1998,352:609-613.
[24]Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy(abstract). In:VII Cochrane Colloquium, Rome, 1999.57.
[25]Schulz KF, Chalmers I, Hayes R et al. Empirical evidence of bias. JAMA,1995,273: 408-412.
[26]Vickers A, Goyal N, Harland R et al. Do certain countries produce only positive results. A systematic review of controlled trials. Control Clin Trials,1998,19:159-166.
[27]中华医典·2.诊法类·2.2脉诊·脉诀刊误·附录·矫世惑脉论
[28]中华医典·1.医经类·1.1内经·1.12类编摘编·类经·四象·十八、老壮少小脂膏肉瘦之别
[29]中华医典·1.医经类·1.3灵枢心得·卷下·卫气失常
[30]中华医典·1.医经类·1.1内经·1.11注释·黄帝内经太素·卷第十一·腧穴·气穴
[31]中华医典·8.综合医书类·医学纲目·卷十六·心小肠部·心痛
[32]龙庆余.从痰疲辨治高脂血症60例[J].安徽中医临床杂志,1998,10(1)：20
[33]中华医典·8.综合医书类·名医杂著·卷之四·风症
[34]中华医典·4方书类·4.1综合方书·4.12宋元方书·仁斋直指方论(附补遗)·卷之七·痰涎·附诸方
[35]中华医典·2诊法类·2.2脉诊·脉义简摩·卷四主病类·郭元峰二十八脉集说·数脉
[36]昌炳如.高脂血症的病因病机与治疗探讨[J].中医研究,2005,18(8)：3.
[37]占新平.高脂血症中医辨证治疗的体会[J].邯郸医学高等专科学校学报,2005,18(1)：47.
[38]王志国,季绍良.高脂血症的病因病机及其证治[J].中医药学刊,2003,21(7)：1149-1150.
[39]钱卫东,庄德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,23(11)：5-6.
[40]郑贵力.王绵之教授治疗高脂血症的学术思想及经验[J].北京中医药大学学报,2000,23(2)：48-51.
[41]杨秀捷,张晨,赵冰.从脾论治高脂血症60例临床观察[J].北京中医,2006,25(1)：11-13.
[42]韩淑亚,张笑峥.高脂血症病因病机研究进展[J].甘肃中医,2001,14(3)：88.
[43]玄瑞英,杨光全.高脂血症的病因及证治探析[J].实用中医内科杂志,2006,20(1)：32.
[44]钱小奇.试论高脂血症的病因病机[J].天津中医,2002,12(19)：6.
[45]龚一萍,宋国平.试论脏腑功能失调与高脂血症形成的相关性[J].中国中医药信息杂志,2001,8(8)：7-8.
[46]高红勤,沈逸辛,钱建明.补肾降脂丸治疗高脂血症临床观察[J].中国中医结合杂志,2001,21(3)：217-218.
[47]佟丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244.
[48]王永林.高脂血症病在心脉,根在肝、脾、肾[J].中国医学研究与临床,2006,4(5)：80-81.
[49]张金生.高脂血症从肝论治初探[J].新中医,2006,38(11)：6-8.
[50]玄瑞英,杨光全.高脂血症的病因及证治探析[J].实用中医内科杂志,2006,20(1)：32.
[51]袁肇凯.高脂血症痰瘀辨证的血脂和血流动力学检测分析[J].湖南中医学院学报,2001,21(3)：1-4.
[52]蒋玉萍,赵玉敏.高脂血症的病因及证治探析[J].中医药学刊,2004,22(6)：1142.
[53]尹亚东.浅析从“痰瘀论治高脂血症”[J].甘肃中医,2006,19(11)：9-10.
[54]金炜,杨红,张承,等.血脂康治疗原发性高脂血症疗效观察[J].中国中西医结合杂志,1997,17(7)：434-435.
[55]李正兰.调脂汤治疗高脂血症疗效观察[J].淮海医药,1998,16(3)：41.
[56]韦湘林,方显明,李锡光,等.调脂口服液治疗高脂血症106例临床疗效观察[J].新中医,1999,31(6)：12-14.
[57]李任先,刘国普,曾益宏,等.理脾化痰降脂片治疗高脂血症的临床研究[J].广州中医药大学学报,1999,16(2)：98-102.
[58]龚少愚,翁晓生.脉络清片治疗高脂血症的临床疗效观察[J].天津中医,1999,16(6)：5-7.
[59]李京.降脂口服液治疗高脂血症210例临床观察[J].北京中医,2001,5：23-25.
[60]崔春黎,周珂杨,罗明,等.复方红曲胶囊治疗高血脂症45例临床观察[J].中成药,2002,24(2)：107-110.
[61]武斌,王静萍.血脂灵治疗高脂血症的临床观察[J].中西医结合心脑血管病杂志,2003,1(9)：554.
[62]杨牧祥,田元祥,刘建东,等.脂调康胶囊治疗高脂血症多中心临床观察[J].河北中医药学报,2003,18(4)：6-10.
[63]蒋兴伟,许宏大,刘德健,等.理脾化痰降脂片治疗高脂血症36例小结[J].湖南中医药导报,2004,10(2)：3-4.
[64]刘宗莲,吴圣贤,高改地.蒲参胶囊治疗高脂血症的临床疗效评价[J].中国中西庆结合杂志,2004,24(3)：227-229.
[65]王晓锋,董海兴,向阳.首乌降脂片治疗高脂血症218例分析[J].中医药学刊,2004,22(6)：1112.
[66]黄民江,邬文敏,蒋乐龙,等.松龄血脉康与多烯康治疗老年高脂血症的疗效比较[J].华西药学杂志,2004,19(6)：481-482.
[67]崔德成,崔丽平.自拟泽泻柴胡汤治疗高脂血症的临床观察[J].北京中医,2004,23(3)：152-153.
[68]杜宝俊,涂秀华,李立志.脂可平软胶囊治疗高脂血症临床研究[J].中国中医药信息杂志,2004,11(9)：757-759.
[69]叶世龙,丁文.脂汰清治疗无症状性高脂血症临床观察[J].中西医结合心脑血管病杂志,2005,3(7)：592-594.
[70]赵秀玲,崔秀兰,田洪英,等.调脂汤治疗高脂血症的疗效观察[J].四川中医,2006,24(4)：52-53.
[71]张笑峥,郭亚权,刘超峰,等.蒲参胶囊治疗瘀血型高脂血症170例临床研究[J].安徽中医学院学报,2006,25(5)：16-17.
[72]朱莹,刘新祥,李向荣,等.乌杞调脂口服液治疗高脂血症临床疗效评价[J].中国中医药信息杂志,2006,13(4)：68-69.
[73]谭嫚娜,林溢涛,张健池.健脾利湿、化痰祛瘀法治疗高脂血症40例临床观察[J].中医药导报,2006,12(5)：21-23.
[74]王爱珍,张艳国.苁蓉调脂胶囊治疗高脂血症例临床观察[J].时珍国医国药,2007,18(9)：2167-2168.
[75]叶世龙,刘爱芹.健脾通脉汤治疗高脂血症临床观察[J].中华中医药杂志,2008,23(10)：916-918.
[76]谢映红,王禹.降脂通络软胶囊治疗高血脂症的临床疗效观察[J].现代中西医结合杂志,2008,17(17)：2640-2641.
[77]赵敏红,王宝才.决明降脂片治疗高脂血症50例观察[J].实用中医药杂志,2008,24(7)：458-459.
[78]赵雅丽.利脉胶囊治疗高脂血症51例临床观察[J].齐鲁护理杂志,2008,14(3)：16-17.
[79]张楠,张杰,刘志礼,等.盾叶冠心宁片治疗高脂血症的临床试验研究[J].中西医结合心脑血管病杂志,2009,7(3)：255-256.
[80]李晓青,周亚新,王影萍,等.降脂宁治原发性高脂血症疗效观察[J].江西中医药,1999,30(5)：19-20.
[81]谭元生,程丑夫,黄大香,等.脂康颗粒剂治疗肝肾阴虚挟瘀型高血脂症的临床研究[J].中国中医药科技,1999,6(4)：213.
[82]佟铭,梁娟.脂苏软胶囊治疗高脂血症120例临床观察[J].现代康复,1999,3(11)：1406.
[83]王翠萍,王培军,苏文革,等.脂泰胶囊治疗高脂血症(痰瘀阻滞证)临床研究[J].中国医药学报,1999,14(6)：38-42.
[84]王东生,周衡,李聚生,等.茵陈五苓散治疗高脂血症的临床观察[J].中国医药学报,2001,16(4)：36-39.
[85]代二庆,王恒和,毛静远,等.松龄血脉康胶囊治疗高脂血症(肝阳上亢证)随机对照临床研究[J].中医药学刊,2003,21(3)：388-390.
[86]王保和,张广明.松龄血脉康胶囊治疗高脂血症(肝阳上亢证)临床有效性和安全性双盲双模拟、阳性药平行对照Ⅱ期临床试验[J].天津中医药,2003,20(1)：58-61.
[87]张翼宙,朱肖鸿.益气活血方治疗血瘀型高脂血症的临床观察[J].浙江临床医学,2003,5(10)：760.
[88]杨惠民,盛彤,韩丽蓓,等.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究[J].中华中医药杂志,2005,20(4)：247-248.
[89]寇秋爱.苏子油软胶囊治疗高脂血症(痰涎阻遏证)临床研究[J].中国实验方剂学杂志,2005,11(4)：67-68.
[90]李伟华,陈静.泽苓降脂胶囊治疗高脂血症60例临床观察[J].甘肃中医,2005,18(12)：18-19.
[91]陈友文.活血降脂颗粒治疗高脂血症的临床观察[J].医药产业资讯,2006,3(14)：88-89.
[92]李大锋,胡有志,蓝小琴,等.心脑致宝平胶囊治疗高脂血症(痰瘀阻遏证)临床研究[J].湖北中医杂志,2008,30(2)：18-19.
[93]宋春晖,陈大舜.健脾化痰补肾降浊治疗高脂血症60例[J].时珍国医国药,2009,20(6)：1540-1541.
[94]张惠鸣.芪蛭胶囊治疗高脂血症58例[J].浙江中医杂志,2009,44(7)：542.
[95]肖洁,袁洪,阳国平,等.刺葡萄籽油软胶囊治疗高脂血症48例总结[J].湖南中医杂志,2006,22(2)：5-6.
[96]丁平,竹剑平.西洋参胶囊治疗高脂血症51例临床观察[J].浙江中医杂志,2009,44(2)：126-127.
[97]高蕊,涂秀华,苗阳,等.以安慰剂为对照评价消瘀降脂胶囊治疗高脂血症Ⅱ期临床试验[J].中国实验方剂学杂志,2007,13(2)：61-64.
[98]陈亮,竹剑平.白藜芦醇治疗高脂血症51例临床疗效观察[J].当代医学,2007,9(124)：127-129.
[99]邢燕军,郭晓峰,陈翠英,等.舒肝降脂胶囊治疗高脂血症的临床研究[J].中国实验方剂学杂志,2002,8(4)：55-57.
[100]邹小玲,林清志,黄流英.更年降脂饮加味治疗高脂血症疗效观察[J].河北中医,2007,29(7)：594-595.
[101]于霞,石闺英.复方丹参注射液加舒降之治疗高脂血症40例疗效观察[J].广东医学院学报,2000,18(3)：307.
[102]宋春晖,纪云西,陈大舜.调脂汤治疗高脂血症临床观察[J].辽宁中医药大学学报,2008,10(8)：88-89.
[103]张永丽.丹参山楂降脂丸治疗高脂血症的临床疗效观察[J].中国医药导报,2009,6(19)：57-58.
[104]徐钢梅,张彩霞,宁丽等,MTT法评价镓合金的细胞毒性[J].中华口腔医学杂志,2001,36(3)：189-192
[105]袁晓亮,海春旭,粱欣等.中药复合抗氧化剂对实验性高脂血症家兔的降脂作用[J].中国临床康复.2003,7(24)：3281-3283.
[106]Wang JP, Ho TF, Chang LC, et al. Anti-inflammatory effect of magnolol, isolated from Magnolia officinalis, on A231872-induced pleurisy in mice[J]. J Pharm Pharmacol,1995,47(10):857-860.
[107]李杰萍,梁统,周克元.厚朴酚对趋化三肽激活的大鼠中性粒细胞功能的影响[J].中国药科大学学报,2003,34(3)：260-263.
[108]林桂芸,谢生发,谢鸿,等.和厚朴酚抑菌作用的研究[J].成都大学学报(自然科学版),2003,22(2)：18-20.
[109]TWOL G. Risk assessment[J]. Evid Based Ment Health,2005,8(4):91-93.
[110]COMBES R, BARRATT M, BALLM S. An overal strategy for the testing of chemicals for human hazard and risk assessment under the EU REACH system[J]. Alter Lab Anim,2003,31(1):7-19.
[111]GRIBALDO L, GENNARI A, BLACKBURN K, et al. Acute toxicity[J]. Altern Lab Anim,2005,33(Suppl):27-34.
[112]BOTHAM PA. Acute systemic toxicity[J]. Ilar J,2002,43(Suppl):27-30.
[113]LI AP. Accurate prediction of human drug toxicity;a major challenge in drug development[J]. Chem Biol Interact,2004,150(1):3-7.
[114]CUNNINGHAM ML. A mouse is not rat is not a human:apeties differences exist[J]. Toxicol Sci,2002.70(2);157-158.
[115]中药、天然药物长期毒性研究技术指导原则[Z](GPT3-1).国家食品药品监督管理局.2005.
[116]药物非临床研究质量管理规范(GLP).国家食品药品监督管理局.2003.
[117]袁伯俊,廖明阳,李波主编.药物毒理学实验方法与技术.北京：化学工业出版社.2007.
[118]毛和平,刘光斌,刘效栓,等.和胃散急性毒性实验研究[J].中国医药导报,2009,6(6)22-23.
[119]靳洪涛,李慧,李晋,等.紫杉胶囊急性毒性和反复给药毒性实验研究[J].中国现代医药杂志,2009,11(5)：12-14.
[120]SCHLEDE E, MISCHKE U, ROLL R, et al. A national validation study of the acute toxic class method:analternative to the LD50 test[J]. Arch Toxicol,1992,66(7): 455-470.
[121]DIENER W, SICCHA L, MISCHKE U, et al. The biometric evaluation of the acute-toxic-class method(oral)[J]. Arch Toxicol,1994,68(10):599-610.
[122]SCHLEDE E, GENSCHOW E, SPIELMANN H, et al. Oral acute toxic class method:a successful alternative to the oral LD50 test[J]. Regul Toxicol Pharmacol, 2005,42(1):15-23.
[123]王丹,宋康,朱社敏,等.椒枝软胶囊大鼠长期毒性实验研究[J].中华中医药学刊,2009,27(12)：2571-2575.
[124]孙学才,贾飞宇,张锦峰.加味四逆散长期毒性实验及安全性评价[J].陕西中医学院学报,2008,31(3)：45-48.
[125]丁芳,韩月芳,郝蕾,等.新冠心苏合活血方长期毒性实验研究[J].河北中医药学报,2009,24(3)：3-6.
[126]杨宜华,陈玉祥,欧阳红涛.黄芪冻干粉对大鼠和狗的长期毒性实验[J].时珍国医国药,2009,20(1)：175-177.
[127]张玉军.外感风痧片对大鼠的长期毒性研究[J].中成药,2009,31(2)：287-290.
[128]朱忠勇主编.实用医学检验学[M].北京：人民军医出版社.1992.
[129]王建伟,王晔,王纪元,等.截瘫康胶囊长期毒性实验及对大白鼠心肝肾等脏器组织结构的影响[J].中医药学报,2005,33(1)：50-52.
[130]孔佑华,王凤琴,张金萍.御力补酒长期毒性试验及对大白鼠心肝肾等脏器组 织结构的影响[J].济宁医学院学报,1999,22(1)：45-47.
[131]武忠弼等主编.中华外科病理学[M].人民卫生出版社.2006：356-357.
[132]苏宁等主编.动物组织病理学图谱[M].东南大学出版社.2005：143.
[133]王捷.毒性病理学[M].辽宁科学技术出版社,2004：76,104.
[134]唐泓皓,王伟,刘斌,等.单味中药土茯苓血清药物化学的初步研究[J].中华中医药杂志,2005,20(6)：342-342.
[135]黄从善,陈婧,刘焱文.复方酸枣仁汤有效部位大鼠血清化学成分分析[J].中国医院药学杂志,2006,26(5)：522-524.
[136]王宇卿,闫明,陈文,等.补骨脂血清药物化学的初步研究[J].中国新药杂志,2008,17(5)：396-399.
[137]刘睿颖,王盛民,宋庆国.多烯紫杉醇脂质体大鼠体内药物动力学研究[J].时珍国医国药,2009,20(1)：56-57.
[138]常明向,徐莲英,陶建生.当归及其配伍药对当归芍药的药动学研究[J].中药药理与临床,1993,8(4)：34-36.
[139]黄熙,文爱东,马援,等.川芎丹参煎剂灌胃大鼠后体内川芎嗪的药物动力学研究[J].中药药理与临床,1993,8(4)：34-36.
[140]戴宇飞,牛勇,程娟.三氯乙烯对致敏豚鼠脾淋巴细胞毒性的体外实验研究[J].中华劳动卫生职业病杂志,2005,23(2)：129-131
[141]赵萧萧,王际辉,叶淑红,等.人参茎叶多糖对小鼠免疫功能的影响[J].中国酿造,2009,3(204)：56-58
[142]罗燕,邵永斌,谷新利,等.中药多糖及其含药血清对小鼠淋巴细胞增殖的影响[J].时珍国医国药,2009,20(6)：1484-1486
[143]马俊鹏,朱卫江,卢冬梅.一枝蒿提取物调节小鼠免疫功能的研究[J].西北药学杂志,2009,24(3)：197-199
[144]王昕,施嬿萍,朱雪涛,等.MTT法评价医用高分子材料的细胞毒性[J].山东生物医学工程,2003,1：46-47
[145]李玉娟,王瑞,车镇涛,等.中药材指纹图谱质量控制方法研究[J].中药新药与临床药理,2001,12(3)：192-195.
[146]戚重桓,倪观峰.高效液相色谱法测定地稔中没食子酸的含量[J].浙江中医杂志,2010,45(3)：220-230.
[147]胥道宝,张转平.叶下珠中鞣质及没食子酸的含量测定[J].西北药学杂志,2008,23(1)：31-32.
[148]叶会呈,叶其馨,王带媚,等HPLC法测定血府逐瘀汤中阿魏酸的含量[J].中药新药与临床药理,2009,20(4)：356-358.
[149]徐凤清,王国凯,刘金旗.高效液相色谱法测定潜朴中厚朴酚及和厚朴酚的含量[J].安徽中医学院学报,2010,29(4)：66-68.
[150]李正杰,李晓燕,张彦芬,等RP-HPLC法测定平胃滴丸中厚朴酚及和厚朴酚的含量[J].食品与药品,2010,12(7)：267-269.
[151]邢立志,暴春艳.HPLC法测定紫草中的左旋紫草素的含量[J].亚太传统医药,2008,4(5)：41-42.
[152]杜春双,宋晓坤.紫黄膏中的左旋紫草素的含量测定[J].中国医院学杂志,2007,27(10)：1468-1469.
[153]王晓辉,刘涛,李清,等.高效液相色谱法同时测定黄芪中的五种异黄酮类成分[J].色谱,2006,24(5)：486-488.
[154]徐青,王龙星,张曦,等.黄芪中黄酮类组分的高效液相色谱分离条件的快速优化[J].色谱,2005,23(11)：630-632.
[155]徐雄良,张志荣,黄园.大黄高效液相色谱法指纹图谱分离条件的优化[J].四川大学学报(医学版),2004,35(4)：559-562.
[156]姜林,李晓瑾,贾晓光.新疆紫草HPLC指纹图谱的研究[J].中成药,2005,27(11)：1241-1244.
[157]刘晓东,闫明,张兰兰,等.高良姜高效液相色谱指纹图谱分离条件的优化[J].中国药业,2009,18(9)：15-17.
[158]Gnabre John Noel, Tto Yoichiro, Ma Ying Huang. Isolation of anti-HIV-I lignans from Larrea tridentatea by counter-current chromatography[J]. J Chromatogr A, 1996(2):353.
[159]Degenhardt A, Engdhardr U H. Preparative separation of polyphenols from tea by high-speed countercurrent chromatography[J]. J Agric Food Chem,2000,48(8): 3425.
[160]Mebius RE, Nolte MA, Kraal G. Development and function of the splenic marginal zone[J]. Crit Rev Immunol,2004,24(6):449-464.
[161]Vander Heyde HC, Batchelder JM, Sandor M, et al. Splenic {gamma}{delta} T Cells Regulated by CD4+T Cells Are Required To Control Chronic Plasmodium chabaudi Malaria in the B-Cell--Deficient Mouse[J]. Infect Immun,2006, 74(5):2717-2725.
[162]Engwerda CR, Beattie L, Amante Fh. The importance of spleen in malaria[J]. Trends Parasitol,2005,21(8):356-357.
[163]韦敏,刘丽敏,刘华钢,等.白花丹素的体外肾毒性及酸性成纤维细胞生长因子对白花丹素所致肾损伤的保护作用[J].药学服务与研究,2009,9(4)：272-274
[164]刘德坚,马忠元,梁敬棠.镉对大鼠肾细胞毒性和脂质过氧化作用的影响[J].中国热带医学,2007,7(10)：1755-1756
[165]韦敏,刘华钢,刘丽敏.氯化两面针碱的体外肾毒性研究[J].时针国医国药,2009,20(9)：2295-2296
[166]沈晓帆,王旗,杨秀伟,等.七叶皂苷肾细胞毒性及抗氧化剂的拮抗作用[J].中国药理学与毒理学杂志,2008,22(5)：375-381
[167]宋东伟,赵文军,吴雪萍,等.阿魏属植物化学成分及药理活性研究进展[J].中成药.2005,27(3)：329-332.
[168]Duwiejua M, Zeitlin IJ, Waterman PG, et al. Antiinflammatory activity of Polygonum bistorta, Guaiacum officinale and Hamamelis virginiana in rats[J]. Pharm Pharmcol,1994,46(4):286-290.
[169]Mahana Duwiejua, Isaac J. Zeitlin, Alexander I. Gray;The anti-inflammatory compounds of Polygonum bistorta:isolation and chara
[170]Bang KH, Kim YK, Min BS, et al. Antifungal activity of mangnolol and honokiol[J]. Arch Pharm Res,2000,23(1):46-49.
[171]冯瑾,李继遥,周学东.厚朴活性成分对致龋菌生长和产酸影响的体外研究[J].四川大学学报(医学版),2007,38(3)：456-458.
[172]Ho KY, Tsai CC, Chen CP, et al. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis[J]. Phytother Res,2001,15(2):139-411.
[173]Park J, Lee J, Jung E, et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. [J]. Eur J Pharmacol,2004, 496(1-3):189-195.
[174]林桂芸,谢生发,谢鸿,等.和厚朴酚抑菌作用的研究[J].成都大学学报(自然科学版),2003,22(2)：18-20.
[175]Wang JP, Ho TF, Chang LC, et al. Anti-inflammatory effect of magnolol, isolated from Magnolia officinalis, on A231872-induced pleurisy in mice[J]. J Pharm Pharmacol,1995,47(10):857-860.
[176]李杰萍,梁统,周克元.厚朴酚对趋化三肽激活的大鼠中性粒细胞功能的影响[J].中国药科大学学报,2003,34(3)：260-263.
[177]Xianhe B, Francesca C, Masuko U, et al. Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesisin Vitro and Tumor Growth in Vivo[J]. J Biol Chem,2003,278(37):35501-35507.
[178]Yang SE, Hsieh MT, Tsai TH, et al. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells[J]. Br J Pharmacol,2003, 138(1):193-201.
[179]Lin SY, Liu JD, Chang HC, et al. Magnololsuppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apotosis[J]. J Cell Biochem,2002,84(3):532-544.
[180]Kenji I, Teru H, Makoto H, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and independent apoptosis[J]. Blood,2005,106:1794-1800.
[181]Fong W, Tse A, Poon K, et al. Magnolol and honokiol enhance HL-60 humanl eukemia cell differentiation induced byl,25-dihydroxyvitamin D3 and retinoic acid[J]. Int J Biochem Cell Biol,2005,37(2):427-441.
[182]Syu WJ, Shen CC, Lu JJ, et al. Antimicrobial and cytotoxic activities of neolignans from Magnolia officinalis[J]. Chem Biodivers,2004, 1(3):530-537.
[183]Chiu JH, Ho CT, Wei YH, et al. In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury[J]. Life Sci,1997,61(19):1961-1971.
[184]Lee YM, Hsiao G, Chen HR, et al. Magnolol reduces myocardial ischemia/ reperfusion injury via neutrophil inhibition in rats[J]. Eur J Pharmacol,2001, 422(3):159-167.
[185]Huang CH, Hong CY, Tsai SK, et al. Intravenous pretreat ment with magnolol protects myocardium against stunning[J]. Planta Med,2000,66(6):516-520.
[186]Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis[J]. Thromb Res,1988,50(6):757-765.
[187]Zhang GQ, Chem SZ, Hao XM, et al. The protective effect of magnolol on cerebral ischemia[J]. Chin Pharmacol Bull,2003,19(9):1020-1023.
[188]Liou KT, Shen YC, Chen CF, et al. Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production [J]. Brain Res,2003,992(2):159-166.
[189]Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis[J]. Thromb Res,1988,50(6):757-765.
[190]Li B, Masukawa N, Yamaki M, et al. Four stilbenoids from Pleione bulbocodioides[J]. Phytochemistry,1998,48(2):327-331.
[191]U. Sankawa, E. Yutaka, M. Trutaka. Antitumor activity of shikonin and its derivatives [J]. Chemical and Pharmaceutical Bulletin.1977.25.2392-2395.
[192]吴振.紫草素诱导肿瘤细胞凋亡机制研究[D].沈阳药科大学,2004.
[193]Sasaki, K., Yoshizaki, F., Abe, H. The anti-Candida activity of shikon[J]. Yakugaku Zasshi,2000,120(6):587-589.
[194]佐佐木健郎.紫草成分的抗真菌活性及其对念珠菌性口腔疾患的改善作用[J].国外医学中医中药分册,2004,26(5)：310.
[195]Kaith, B. S., Kaith, N. S., Chauhan, N. S Anti-inflammatory effect of Arnebia euchroma root extracts in rats[J]. Journal of Ethnopharmacology,1996,55:77-80.
[196]王文杰,白金叶,刘大培,等.紫草素抗炎及对白三烯B4生物合成的抑制作用[J].药学学报,1994,29(3)：161-165.
[197]Singh B., Sharma, M. K., Meghwal, P. R., Sahu, P. M., and Singh S. Anti-inflammatory activity of shikonin derivatives from Arnebia hispidissima[J]. Phytomedicine,2003,10:375-380.
[198]刘燕,买尔旦·马合木提,尼加提·热合木.新疆紫草提取物对小鼠急性四氯化碳性肝损伤的保护作用[J].时珍国医国药,2006,17(9)：1676-1678.
[199]买尔旦·马合木提,刘燕,尼加提·热合木.新疆紫草提取物对D一氨基半乳糖致小鼠急性肝损伤的保护作用[J].中国中药杂志,2006,31(19)：1646-1649.
[200]Yamasaki K, Otake T, Mori H, Morimoto M, Ueba N, Kurokawa Y, Shiota K, Yuge T. Screening test of crude drug extract on anti-HIV activity[J]. Yakugaku Zasshi, 1993,113(11):818-24.
[201]江苏新医学院.中药大辞典[M],上海：上海人民出版社,1977,721-723.
[202]孙立彦,刘振亮,孙金霞,等.白茅根多糖对小鼠耐缺氧作用的影响[J].中国医院药学杂志,2008,28(2)：96-99.
[203]岳兴如,侯宗霞,刘萍,等.白茅根抗炎的药理作用[J].中国临床康复,2006,10(43)：85-87.
[204]付嘉,熊斌,白丰沛,等.白茅根对小鼠细胞免疫功能影响[J].黑龙江医药科学,2000,23(2)：17.
[205]焦坤,陈佩东,和颖颖,等.白茅根研究概况[J].江苏中医药,2008,40(1)：91-93.
[1]郭玉民,呼子奇.高脂血症的防治[J].中国水电医学,2009,1：42-43.
[2]韦侃侃,胡滨山,张莉蓉ABCG8 T400K基因多态性与高脂血症的关系[J].河南预防医学杂志,2009,20(4)：246.
[3]容春莉,彭应心,刘美霞,王秀萍,宋津晓.中国北方汉族人载脂蛋白E基因多态性与血脂代谢的关系[J].中国现代医学杂志.2008.18(5)：586.
[4]孙赞,李玲,马庆宏.载脂蛋白E基因多态性与血脂和冠状动脉粥样硬化性心脏病相关性的研究[J].辽宁医学杂志,2008,22(1)：7.
[5]张培珍,田野ApoB、ApoE基因多态性与血脂异常的关系及运动训练的影响.[J]体育科学,2006,26(10)：65.
[6]李溪,姚成立,宋梅,等.载脂蛋白A5基因56C>G多态性与血甘油三酯相关性的研究[J].宁夏医学杂志,2006,28(9)：643.
[7]赵水平,肖志杰,李全忠,等.ATP结合盒转运子A1基因R219K变异对血脂的影响[J].中华医学杂志,2004,84(17)：1421.
[8]唐和年,张总刚,杜宇奎.新疆汉族和维吾尔族健康人群VKORC1启动子区基因多态性研究[J].中国优生与遗传杂志.2007,15(3)：16.
[9]杨胜利,何秉贤,何作云,等.新疆维汉两民族冠心病患者载脂蛋白E基因多态性研究[J].中国微循环,2004,8(1)：21
[10]李涛,李南方,周玲.新疆哈萨克族人群中血脂水平与AT1R基因A1166C多态性的相关研究[J].心脑血管病防治,2007,7(1)：4
[11]苏蓉,于德水.高脂血症的危害及防治[J].疾病防控,2009,16(8)：128-129.[12]吕瑞娟,张运,陈玉国,等.他汀类药物治疗ALT升高的急性冠状动脉综合征的可行性研究[J].新医学,2006,37(6)：368-369.
[13]吴家恩.阿托伐他汀钙治疗高脂血症的疗效观察[J].医药世界,2009,11(8)：414.
[14]金志泽.辛伐他汀的降脂疗效及对颈动脉粥样硬化的影响[J].中国综合临床,2002,18(1)：44-45.
[15]尤丽吐孜·努尔,温切木·吾斯曼.不同剂量舒降之治疗肾病综合征合并高脂血症的疗效观察[J].中外医疗,2009,22：93.
[16]佟以东,李铁柱.不同剂量辛伐他汀治疗冠心病合并高血脂症的疗效和安全性观察[J].黑龙江医学,2006,30(4)：278-279.
[17]阚光树,何道荣.氟伐他汀治疗高脂血症患者的疗效观察[J].华西医学,2009,24(1)：118-119.
[18]张利璧,冯玉宝.血脂异常治疗新进展[J].中国误诊学杂志,2005, 5(15)：2824-2825.
[19]唐丽洁,范昱,朱有华.非诺贝特对肾移植后高脂血症环孢素浓度影响[].医药论坛杂志,2008,29(8)：1-2.
[20]赵进,韦建瑞,吴同果.烟酸缓释片治疗混合性高脂血症的疗效[J].广东医学,2008,29(8)：1402-1403.
[21]JEFFREY T, AL IA, ALAW IA, et a.1 High-density Lipoprotein Cholesterol-Raising Strategies [J]. J Card Phann aco 1,2006,47(2):196.
[22]GANJI SH, KAMANNA V S, KASHYAP M L. N iacin and cholestero:l role in card iovascu lar d isease[J]. Jnu tr Bioch en,2003,14(6):298-305.
[23]汪艺,郑峰,张小平.阿昔莫司联合普伐他汀治疗老年混合型高脂血症的疗效与安全性[J].中国老年保健医学,2008,6(4)：23-25.
[24]Guyton JR, Buy HE. Safety considerations with Niacin therapy[J]. Am J Cardiol, 2007,99(6A):22C-31C.
[25]Taylor A J, Sullenberger LE, Lee H J, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol(ARBITER)2.A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins[J]. Circulation,2004,110:3512-3517.
[26]李卫群,陈华萍.辛伐他汀联合藻酸双脂钠治疗高胆固醇血症及高脂血症的临床观察[J].广东医学院学报,2005,23(2)：187-188.
[27]宫旭海,杨彩云,赵春环,等.甘糖酯、立普妥对脑梗塞合并高脂血症患者降脂疗效对比[J].中国实验诊断学,2008,12(12)：1599-1600.
[28]徐庆,刘英华,王觐,等.中长链脂肪酸食用油对高甘油三酯血症患者脂代谢的影响[J].军医进修学院学报,2009,30(4)：511.
[29]张红岩.多烯酸乙酯康胶丸治疗高脂血症30例调查分析[J].中国现代药物应用,2008,2(16)：34-35.
[30]杨彦平.弹性酶治疗高脂血症伴非酒精性脂肪肝的临床观察[J].中国现代药物应用,2009,3(3)：77-78.
[31]王云,柯元南,王嘉莉,等.多廿烷醇与普伐他汀治疗高脂血症的疗效和安全性[J].中国新药与临床杂志,2008,27(2)：124-127.
[32]李燕华,安英娣.谷维素调脂作用临床观察[J].临床荟瘁,2003,18(5)：274.
[33]何解生.谷维素的临床新用途[J].实用药物与临床,2006,9(2)：110-111.
[34]钟湘,杨文君,吴禹.谷维素合并维生素E治疗高脂血症的临床观察[J].第三军医大学学报,2007,29(11)：1128.
[35]A ccinn iR, Ros ina M, Bam on ti F, et al. E ffects of com bined d ietary supplem en tat ion on oxidat ive and in flamm atory statu s in dyslipidem icsub jects[J]. Nu trM etab Card iovasc Dis,2006,16(2):121-127.
[36]饶刚,唐学文.云芝胞内多糖治疗高血脂症作用的临床观察[J].重庆医学,2007,36(13)：1306-1307.
[37]Sirtori CR, Calabresi L, Ferrara S, et al. L2carnitine reducesp lasma lipop rotein(a)levels in patientswith hyper Lp(a)[J]. NutrMetab Cardiovasc Dis,2000, 10(5):247-251.
[38]Argani H, RahbaninoubarM, Ghorbanihagjo A, et al. Effect of Lcarnitine on the serum lipoproteins and HDL-C subclasses in hemodialysis patients [J]. Nephron Clin Pract,2005,101(4):174-179.
[39]Gunes B, Yalcin SS, Kalkanoglu HS, et al. The effect of oral Lcarnitine supp lementation on the lipid profiles of hyperlipideamic children[J]. Acta Paediatr,2005, 94(6):711-716.
[40]许宏安,施陈刚.辛伐他汀非诺贝特交替治疗混合性高脂血症安全性、有效性观察[J].浙江临床医学,2006,8(1)：38.
[41]孙晓红,彭晓玲,朱蕾.小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症临床疗效及安全性[J].中华高血压杂志,2007,15(5)：387.
[42]AronowW S. Pharmacologic therapy of lipid disorders in the elderly [J]. Arm J Geriatr Cariol,2002,11(4):247-256
[43]乔淑章,陈莉,康文巧,等.半导体激光穴位照射治疗高脂血症60例[J].河北中医,2005,27(3)：208.
[44]关敏.磁极化血液净化冷凝离子吸附治疗高脂血症、高粘血症[J].中国水电医学,2005,1：9-10.
[45]陆明晰,胡卫民,冯剑,等.二重血浆分离治疗高脂血症及急性高脂血症性胰腺炎[J].全科医学临床与教育,2007,5(5)：372-374.
[46]周丽萍,朱彩侠.高压臭氧联合调脂汤治疗高脂血症98例[J].陕西中医,2009,30(6)：680-681.
[47]王堂明,邱波.血液灌流治疗高脂血症的临床研究[J].透析与人工器官,2006,17(4)：28-29.
[48]赵奕华,邢昌赢,邹元国,等.中国血液净化,2008,7(1)：19-20.
[49]冉君花,刘辉.营养联合运动治疗对高脂血症患者血脂的影响[J].中国疗养医学,2009,18(2)：102-103.
[2]王新陆·脑血辨证[M].北京：中国医药科技出版社,2002：82-99
[3]韩淑亚,张笑峥.高脂血症病因病机研究进展[J].甘肃中医,2001,14(3)：88-90
[4]王宪波.中西医治疗冠心病[M].北京：中国中医药出版社,1995：206-207
[5]刘进,常建军,刘侃,等.降脂口服液治疗原发性高脂血症疗效观察[J].中医研究,1993,6(2)：22.
[6]孙丽英,焦亚斌,康广盛.高脂血证的病因病机研究进展[J].中医药学报,2004,32(2)：70-71
[7]钱卫东,钱小奇.高脂血证中医论治法则探讨[J].陕西中医,2002,22(8)：712-713.
[8]佟丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244
[9]中华医典·4方书类·4.1综合方书·4.12宋元方书·仁斋直指方论(附补遗)·卷之七·痰涎·附诸方
[10]王中琳,王新陆.从“血浊”辨治高脂血症经验[J].山东中医药大学学报,2007,31(6)：474-475.
[11]张玉珍.中医妇科学[M].北京：人民卫生出版社,2001：122.
[12]卓鹏伟,吴鸿洲.浅析叶天士瘕证治[J].中国中医急症,2010,19(7)：1171.
[13]中华医典·1.医经类·1.1灵枢·1.31注释·黄帝内经灵枢集注·卷五·逆顺肥瘦第三十八
[14]中华医典·3本草类·3.1综合本草·3.13明代本草·本草纲目·主治第三卷·百病主治药·下血
[15]卓鹏伟,吴鸿洲.浅析叶天士瘕证治[J].中国中医急症,2010,19(7)：1204.
[16]中华医典·本草类·综合本草·玉楸药解·卷二·木部
[17]中华医典·3本草类·3.1综合本草·3.13明代本草·神农本草经疏·卷十一·草部下品之下·山慈菇
[18]中华医典·3本草类·3.1综合本草·3.14清代本草·本草新编·卷之四(徵集)·山慈菇根
[19]祝世讷.转化生效—中药的复杂功效机制[J].2008,32(3)：179.
[20]Marineola FM. Translational medicine:a two-way road[J]. J Transl Med,2003, 1(1):1.
[21]蒋跃绒,陈可冀.转化医学与中西医结合的研究和发展[J].中国中西医结合杂 志,2010,30(10)：1017-1020.
[22]Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials:Is blinding necessary? Control Clin Trials 1996,17:1-12.
[23]Moher D, Pham B, Jones A et al. Dose quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet,1998,352:609-613.
[24]Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy(abstract). In:VII Cochrane Colloquium, Rome, 1999.57.
[25]Schulz KF, Chalmers I, Hayes R et al. Empirical evidence of bias. JAMA,1995,273: 408-412.
[26]Vickers A, Goyal N, Harland R et al. Do certain countries produce only positive results. A systematic review of controlled trials. Control Clin Trials,1998,19:159-166.
[27]中华医典·2.诊法类·2.2脉诊·脉诀刊误·附录·矫世惑脉论
[28]中华医典·1.医经类·1.1内经·1.12类编摘编·类经·四象·十八、老壮少小脂膏肉瘦之别
[29]中华医典·1.医经类·1.3灵枢心得·卷下·卫气失常
[30]中华医典·1.医经类·1.1内经·1.11注释·黄帝内经太素·卷第十一·腧穴·气穴
[31]中华医典·8.综合医书类·医学纲目·卷十六·心小肠部·心痛
[32]龙庆余.从痰疲辨治高脂血症60例[J].安徽中医临床杂志,1998,10(1)：20
[33]中华医典·8.综合医书类·名医杂著·卷之四·风症
[34]中华医典·4方书类·4.1综合方书·4.12宋元方书·仁斋直指方论(附补遗)·卷之七·痰涎·附诸方
[35]中华医典·2诊法类·2.2脉诊·脉义简摩·卷四主病类·郭元峰二十八脉集说·数脉
[36]昌炳如.高脂血症的病因病机与治疗探讨[J].中医研究,2005,18(8)：3.
[37]占新平.高脂血症中医辨证治疗的体会[J].邯郸医学高等专科学校学报,2005,18(1)：47.
[38]王志国,季绍良.高脂血症的病因病机及其证治[J].中医药学刊,2003,21(7)：1149-1150.
[39]钱卫东,庄德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,23(11)：5-6.
[40]郑贵力.王绵之教授治疗高脂血症的学术思想及经验[J].北京中医药大学学报,2000,23(2)：48-51.
[41]杨秀捷,张晨,赵冰.从脾论治高脂血症60例临床观察[J].北京中医,2006,25(1)：11-13.
[42]韩淑亚,张笑峥.高脂血症病因病机研究进展[J].甘肃中医,2001,14(3)：88.
[43]玄瑞英,杨光全.高脂血症的病因及证治探析[J].实用中医内科杂志,2006,20(1)：32.
[44]钱小奇.试论高脂血症的病因病机[J].天津中医,2002,12(19)：6.
[45]龚一萍,宋国平.试论脏腑功能失调与高脂血症形成的相关性[J].中国中医药信息杂志,2001,8(8)：7-8.
[46]高红勤,沈逸辛,钱建明.补肾降脂丸治疗高脂血症临床观察[J].中国中医结合杂志,2001,21(3)：217-218.
[47]佟丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244.
[48]王永林.高脂血症病在心脉,根在肝、脾、肾[J].中国医学研究与临床,2006,4(5)：80-81.
[49]张金生.高脂血症从肝论治初探[J].新中医,2006,38(11)：6-8.
[50]玄瑞英,杨光全.高脂血症的病因及证治探析[J].实用中医内科杂志,2006,20(1)：32.
[51]袁肇凯.高脂血症痰瘀辨证的血脂和血流动力学检测分析[J].湖南中医学院学报,2001,21(3)：1-4.
[52]蒋玉萍,赵玉敏.高脂血症的病因及证治探析[J].中医药学刊,2004,22(6)：1142.
[53]尹亚东.浅析从“痰瘀论治高脂血症”[J].甘肃中医,2006,19(11)：9-10.
[54]金炜,杨红,张承,等.血脂康治疗原发性高脂血症疗效观察[J].中国中西医结合杂志,1997,17(7)：434-435.
[55]李正兰.调脂汤治疗高脂血症疗效观察[J].淮海医药,1998,16(3)：41.
[56]韦湘林,方显明,李锡光,等.调脂口服液治疗高脂血症106例临床疗效观察[J].新中医,1999,31(6)：12-14.
[57]李任先,刘国普,曾益宏,等.理脾化痰降脂片治疗高脂血症的临床研究[J].广州中医药大学学报,1999,16(2)：98-102.
[58]龚少愚,翁晓生.脉络清片治疗高脂血症的临床疗效观察[J].天津中医,1999,16(6)：5-7.
[59]李京.降脂口服液治疗高脂血症210例临床观察[J].北京中医,2001,5：23-25.
[60]崔春黎,周珂杨,罗明,等.复方红曲胶囊治疗高血脂症45例临床观察[J].中成药,2002,24(2)：107-110.
[61]武斌,王静萍.血脂灵治疗高脂血症的临床观察[J].中西医结合心脑血管病杂志,2003,1(9)：554.
[62]杨牧祥,田元祥,刘建东,等.脂调康胶囊治疗高脂血症多中心临床观察[J].河北中医药学报,2003,18(4)：6-10.
[63]蒋兴伟,许宏大,刘德健,等.理脾化痰降脂片治疗高脂血症36例小结[J].湖南中医药导报,2004,10(2)：3-4.
[64]刘宗莲,吴圣贤,高改地.蒲参胶囊治疗高脂血症的临床疗效评价[J].中国中西庆结合杂志,2004,24(3)：227-229.
[65]王晓锋,董海兴,向阳.首乌降脂片治疗高脂血症218例分析[J].中医药学刊,2004,22(6)：1112.
[66]黄民江,邬文敏,蒋乐龙,等.松龄血脉康与多烯康治疗老年高脂血症的疗效比较[J].华西药学杂志,2004,19(6)：481-482.
[67]崔德成,崔丽平.自拟泽泻柴胡汤治疗高脂血症的临床观察[J].北京中医,2004,23(3)：152-153.
[68]杜宝俊,涂秀华,李立志.脂可平软胶囊治疗高脂血症临床研究[J].中国中医药信息杂志,2004,11(9)：757-759.
[69]叶世龙,丁文.脂汰清治疗无症状性高脂血症临床观察[J].中西医结合心脑血管病杂志,2005,3(7)：592-594.
[70]赵秀玲,崔秀兰,田洪英,等.调脂汤治疗高脂血症的疗效观察[J].四川中医,2006,24(4)：52-53.
[71]张笑峥,郭亚权,刘超峰,等.蒲参胶囊治疗瘀血型高脂血症170例临床研究[J].安徽中医学院学报,2006,25(5)：16-17.
[72]朱莹,刘新祥,李向荣,等.乌杞调脂口服液治疗高脂血症临床疗效评价[J].中国中医药信息杂志,2006,13(4)：68-69.
[73]谭嫚娜,林溢涛,张健池.健脾利湿、化痰祛瘀法治疗高脂血症40例临床观察[J].中医药导报,2006,12(5)：21-23.
[74]王爱珍,张艳国.苁蓉调脂胶囊治疗高脂血症例临床观察[J].时珍国医国药,2007,18(9)：2167-2168.
[75]叶世龙,刘爱芹.健脾通脉汤治疗高脂血症临床观察[J].中华中医药杂志,2008,23(10)：916-918.
[76]谢映红,王禹.降脂通络软胶囊治疗高血脂症的临床疗效观察[J].现代中西医结合杂志,2008,17(17)：2640-2641.
[77]赵敏红,王宝才.决明降脂片治疗高脂血症50例观察[J].实用中医药杂志,2008,24(7)：458-459.
[78]赵雅丽.利脉胶囊治疗高脂血症51例临床观察[J].齐鲁护理杂志,2008,14(3)：16-17.
[79]张楠,张杰,刘志礼,等.盾叶冠心宁片治疗高脂血症的临床试验研究[J].中西医结合心脑血管病杂志,2009,7(3)：255-256.
[80]李晓青,周亚新,王影萍,等.降脂宁治原发性高脂血症疗效观察[J].江西中医药,1999,30(5)：19-20.
[81]谭元生,程丑夫,黄大香,等.脂康颗粒剂治疗肝肾阴虚挟瘀型高血脂症的临床研究[J].中国中医药科技,1999,6(4)：213.
[82]佟铭,梁娟.脂苏软胶囊治疗高脂血症120例临床观察[J].现代康复,1999,3(11)：1406.
[83]王翠萍,王培军,苏文革,等.脂泰胶囊治疗高脂血症(痰瘀阻滞证)临床研究[J].中国医药学报,1999,14(6)：38-42.
[84]王东生,周衡,李聚生,等.茵陈五苓散治疗高脂血症的临床观察[J].中国医药学报,2001,16(4)：36-39.
[85]代二庆,王恒和,毛静远,等.松龄血脉康胶囊治疗高脂血症(肝阳上亢证)随机对照临床研究[J].中医药学刊,2003,21(3)：388-390.
[86]王保和,张广明.松龄血脉康胶囊治疗高脂血症(肝阳上亢证)临床有效性和安全性双盲双模拟、阳性药平行对照Ⅱ期临床试验[J].天津中医药,2003,20(1)：58-61.
[87]张翼宙,朱肖鸿.益气活血方治疗血瘀型高脂血症的临床观察[J].浙江临床医学,2003,5(10)：760.
[88]杨惠民,盛彤,韩丽蓓,等.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究[J].中华中医药杂志,2005,20(4)：247-248.
[89]寇秋爱.苏子油软胶囊治疗高脂血症(痰涎阻遏证)临床研究[J].中国实验方剂学杂志,2005,11(4)：67-68.
[90]李伟华,陈静.泽苓降脂胶囊治疗高脂血症60例临床观察[J].甘肃中医,2005,18(12)：18-19.
[91]陈友文.活血降脂颗粒治疗高脂血症的临床观察[J].医药产业资讯,2006,3(14)：88-89.
[92]李大锋,胡有志,蓝小琴,等.心脑致宝平胶囊治疗高脂血症(痰瘀阻遏证)临床研究[J].湖北中医杂志,2008,30(2)：18-19.
[93]宋春晖,陈大舜.健脾化痰补肾降浊治疗高脂血症60例[J].时珍国医国药,2009,20(6)：1540-1541.
[94]张惠鸣.芪蛭胶囊治疗高脂血症58例[J].浙江中医杂志,2009,44(7)：542.
[95]肖洁,袁洪,阳国平,等.刺葡萄籽油软胶囊治疗高脂血症48例总结[J].湖南中医杂志,2006,22(2)：5-6.
[96]丁平,竹剑平.西洋参胶囊治疗高脂血症51例临床观察[J].浙江中医杂志,2009,44(2)：126-127.
[97]高蕊,涂秀华,苗阳,等.以安慰剂为对照评价消瘀降脂胶囊治疗高脂血症Ⅱ期临床试验[J].中国实验方剂学杂志,2007,13(2)：61-64.
[98]陈亮,竹剑平.白藜芦醇治疗高脂血症51例临床疗效观察[J].当代医学,2007,9(124)：127-129.
[99]邢燕军,郭晓峰,陈翠英,等.舒肝降脂胶囊治疗高脂血症的临床研究[J].中国实验方剂学杂志,2002,8(4)：55-57.
[100]邹小玲,林清志,黄流英.更年降脂饮加味治疗高脂血症疗效观察[J].河北中医,2007,29(7)：594-595.
[101]于霞,石闺英.复方丹参注射液加舒降之治疗高脂血症40例疗效观察[J].广东医学院学报,2000,18(3)：307.
[102]宋春晖,纪云西,陈大舜.调脂汤治疗高脂血症临床观察[J].辽宁中医药大学学报,2008,10(8)：88-89.
[103]张永丽.丹参山楂降脂丸治疗高脂血症的临床疗效观察[J].中国医药导报,2009,6(19)：57-58.
[104]徐钢梅,张彩霞,宁丽等,MTT法评价镓合金的细胞毒性[J].中华口腔医学杂志,2001,36(3)：189-192
[105]袁晓亮,海春旭,粱欣等.中药复合抗氧化剂对实验性高脂血症家兔的降脂作用[J].中国临床康复.2003,7(24)：3281-3283.
[106]Wang JP, Ho TF, Chang LC, et al. Anti-inflammatory effect of magnolol, isolated from Magnolia officinalis, on A231872-induced pleurisy in mice[J]. J Pharm Pharmacol,1995,47(10):857-860.
[107]李杰萍,梁统,周克元.厚朴酚对趋化三肽激活的大鼠中性粒细胞功能的影响[J].中国药科大学学报,2003,34(3)：260-263.
[108]林桂芸,谢生发,谢鸿,等.和厚朴酚抑菌作用的研究[J].成都大学学报(自然科学版),2003,22(2)：18-20.
[109]TWOL G. Risk assessment[J]. Evid Based Ment Health,2005,8(4):91-93.
[110]COMBES R, BARRATT M, BALLM S. An overal strategy for the testing of chemicals for human hazard and risk assessment under the EU REACH system[J]. Alter Lab Anim,2003,31(1):7-19.
[111]GRIBALDO L, GENNARI A, BLACKBURN K, et al. Acute toxicity[J]. Altern Lab Anim,2005,33(Suppl):27-34.
[112]BOTHAM PA. Acute systemic toxicity[J]. Ilar J,2002,43(Suppl):27-30.
[113]LI AP. Accurate prediction of human drug toxicity;a major challenge in drug development[J]. Chem Biol Interact,2004,150(1):3-7.
[114]CUNNINGHAM ML. A mouse is not rat is not a human:apeties differences exist[J]. Toxicol Sci,2002.70(2);157-158.
[115]中药、天然药物长期毒性研究技术指导原则[Z](GPT3-1).国家食品药品监督管理局.2005.
[116]药物非临床研究质量管理规范(GLP).国家食品药品监督管理局.2003.
[117]袁伯俊,廖明阳,李波主编.药物毒理学实验方法与技术.北京：化学工业出版社.2007.
[118]毛和平,刘光斌,刘效栓,等.和胃散急性毒性实验研究[J].中国医药导报,2009,6(6)22-23.
[119]靳洪涛,李慧,李晋,等.紫杉胶囊急性毒性和反复给药毒性实验研究[J].中国现代医药杂志,2009,11(5)：12-14.
[120]SCHLEDE E, MISCHKE U, ROLL R, et al. A national validation study of the acute toxic class method:analternative to the LD50 test[J]. Arch Toxicol,1992,66(7): 455-470.
[121]DIENER W, SICCHA L, MISCHKE U, et al. The biometric evaluation of the acute-toxic-class method(oral)[J]. Arch Toxicol,1994,68(10):599-610.
[122]SCHLEDE E, GENSCHOW E, SPIELMANN H, et al. Oral acute toxic class method:a successful alternative to the oral LD50 test[J]. Regul Toxicol Pharmacol, 2005,42(1):15-23.
[123]王丹,宋康,朱社敏,等.椒枝软胶囊大鼠长期毒性实验研究[J].中华中医药学刊,2009,27(12)：2571-2575.
[124]孙学才,贾飞宇,张锦峰.加味四逆散长期毒性实验及安全性评价[J].陕西中医学院学报,2008,31(3)：45-48.
[125]丁芳,韩月芳,郝蕾,等.新冠心苏合活血方长期毒性实验研究[J].河北中医药学报,2009,24(3)：3-6.
[126]杨宜华,陈玉祥,欧阳红涛.黄芪冻干粉对大鼠和狗的长期毒性实验[J].时珍国医国药,2009,20(1)：175-177.
[127]张玉军.外感风痧片对大鼠的长期毒性研究[J].中成药,2009,31(2)：287-290.
[128]朱忠勇主编.实用医学检验学[M].北京：人民军医出版社.1992.
[129]王建伟,王晔,王纪元,等.截瘫康胶囊长期毒性实验及对大白鼠心肝肾等脏器组织结构的影响[J].中医药学报,2005,33(1)：50-52.
[130]孔佑华,王凤琴,张金萍.御力补酒长期毒性试验及对大白鼠心肝肾等脏器组 织结构的影响[J].济宁医学院学报,1999,22(1)：45-47.
[131]武忠弼等主编.中华外科病理学[M].人民卫生出版社.2006：356-357.
[132]苏宁等主编.动物组织病理学图谱[M].东南大学出版社.2005：143.
[133]王捷.毒性病理学[M].辽宁科学技术出版社,2004：76,104.
[134]唐泓皓,王伟,刘斌,等.单味中药土茯苓血清药物化学的初步研究[J].中华中医药杂志,2005,20(6)：342-342.
[135]黄从善,陈婧,刘焱文.复方酸枣仁汤有效部位大鼠血清化学成分分析[J].中国医院药学杂志,2006,26(5)：522-524.
[136]王宇卿,闫明,陈文,等.补骨脂血清药物化学的初步研究[J].中国新药杂志,2008,17(5)：396-399.
[137]刘睿颖,王盛民,宋庆国.多烯紫杉醇脂质体大鼠体内药物动力学研究[J].时珍国医国药,2009,20(1)：56-57.
[138]常明向,徐莲英,陶建生.当归及其配伍药对当归芍药的药动学研究[J].中药药理与临床,1993,8(4)：34-36.
[139]黄熙,文爱东,马援,等.川芎丹参煎剂灌胃大鼠后体内川芎嗪的药物动力学研究[J].中药药理与临床,1993,8(4)：34-36.
[140]戴宇飞,牛勇,程娟.三氯乙烯对致敏豚鼠脾淋巴细胞毒性的体外实验研究[J].中华劳动卫生职业病杂志,2005,23(2)：129-131
[141]赵萧萧,王际辉,叶淑红,等.人参茎叶多糖对小鼠免疫功能的影响[J].中国酿造,2009,3(204)：56-58
[142]罗燕,邵永斌,谷新利,等.中药多糖及其含药血清对小鼠淋巴细胞增殖的影响[J].时珍国医国药,2009,20(6)：1484-1486
[143]马俊鹏,朱卫江,卢冬梅.一枝蒿提取物调节小鼠免疫功能的研究[J].西北药学杂志,2009,24(3)：197-199
[144]王昕,施嬿萍,朱雪涛,等.MTT法评价医用高分子材料的细胞毒性[J].山东生物医学工程,2003,1：46-47
[145]李玉娟,王瑞,车镇涛,等.中药材指纹图谱质量控制方法研究[J].中药新药与临床药理,2001,12(3)：192-195.
[146]戚重桓,倪观峰.高效液相色谱法测定地稔中没食子酸的含量[J].浙江中医杂志,2010,45(3)：220-230.
[147]胥道宝,张转平.叶下珠中鞣质及没食子酸的含量测定[J].西北药学杂志,2008,23(1)：31-32.
[148]叶会呈,叶其馨,王带媚,等HPLC法测定血府逐瘀汤中阿魏酸的含量[J].中药新药与临床药理,2009,20(4)：356-358.
[149]徐凤清,王国凯,刘金旗.高效液相色谱法测定潜朴中厚朴酚及和厚朴酚的含量[J].安徽中医学院学报,2010,29(4)：66-68.
[150]李正杰,李晓燕,张彦芬,等RP-HPLC法测定平胃滴丸中厚朴酚及和厚朴酚的含量[J].食品与药品,2010,12(7)：267-269.
[151]邢立志,暴春艳.HPLC法测定紫草中的左旋紫草素的含量[J].亚太传统医药,2008,4(5)：41-42.
[152]杜春双,宋晓坤.紫黄膏中的左旋紫草素的含量测定[J].中国医院学杂志,2007,27(10)：1468-1469.
[153]王晓辉,刘涛,李清,等.高效液相色谱法同时测定黄芪中的五种异黄酮类成分[J].色谱,2006,24(5)：486-488.
[154]徐青,王龙星,张曦,等.黄芪中黄酮类组分的高效液相色谱分离条件的快速优化[J].色谱,2005,23(11)：630-632.
[155]徐雄良,张志荣,黄园.大黄高效液相色谱法指纹图谱分离条件的优化[J].四川大学学报(医学版),2004,35(4)：559-562.
[156]姜林,李晓瑾,贾晓光.新疆紫草HPLC指纹图谱的研究[J].中成药,2005,27(11)：1241-1244.
[157]刘晓东,闫明,张兰兰,等.高良姜高效液相色谱指纹图谱分离条件的优化[J].中国药业,2009,18(9)：15-17.
[158]Gnabre John Noel, Tto Yoichiro, Ma Ying Huang. Isolation of anti-HIV-I lignans from Larrea tridentatea by counter-current chromatography[J]. J Chromatogr A, 1996(2):353.
[159]Degenhardt A, Engdhardr U H. Preparative separation of polyphenols from tea by high-speed countercurrent chromatography[J]. J Agric Food Chem,2000,48(8): 3425.
[160]Mebius RE, Nolte MA, Kraal G. Development and function of the splenic marginal zone[J]. Crit Rev Immunol,2004,24(6):449-464.
[161]Vander Heyde HC, Batchelder JM, Sandor M, et al. Splenic {gamma}{delta} T Cells Regulated by CD4+T Cells Are Required To Control Chronic Plasmodium chabaudi Malaria in the B-Cell--Deficient Mouse[J]. Infect Immun,2006, 74(5):2717-2725.
[162]Engwerda CR, Beattie L, Amante Fh. The importance of spleen in malaria[J]. Trends Parasitol,2005,21(8):356-357.
[163]韦敏,刘丽敏,刘华钢,等.白花丹素的体外肾毒性及酸性成纤维细胞生长因子对白花丹素所致肾损伤的保护作用[J].药学服务与研究,2009,9(4)：272-274
[164]刘德坚,马忠元,梁敬棠.镉对大鼠肾细胞毒性和脂质过氧化作用的影响[J].中国热带医学,2007,7(10)：1755-1756
[165]韦敏,刘华钢,刘丽敏.氯化两面针碱的体外肾毒性研究[J].时针国医国药,2009,20(9)：2295-2296
[166]沈晓帆,王旗,杨秀伟,等.七叶皂苷肾细胞毒性及抗氧化剂的拮抗作用[J].中国药理学与毒理学杂志,2008,22(5)：375-381
[167]宋东伟,赵文军,吴雪萍,等.阿魏属植物化学成分及药理活性研究进展[J].中成药.2005,27(3)：329-332.
[168]Duwiejua M, Zeitlin IJ, Waterman PG, et al. Antiinflammatory activity of Polygonum bistorta, Guaiacum officinale and Hamamelis virginiana in rats[J]. Pharm Pharmcol,1994,46(4):286-290.
[169]Mahana Duwiejua, Isaac J. Zeitlin, Alexander I. Gray;The anti-inflammatory compounds of Polygonum bistorta:isolation and chara
[170]Bang KH, Kim YK, Min BS, et al. Antifungal activity of mangnolol and honokiol[J]. Arch Pharm Res,2000,23(1):46-49.
[171]冯瑾,李继遥,周学东.厚朴活性成分对致龋菌生长和产酸影响的体外研究[J].四川大学学报(医学版),2007,38(3)：456-458.
[172]Ho KY, Tsai CC, Chen CP, et al. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis[J]. Phytother Res,2001,15(2):139-411.
[173]Park J, Lee J, Jung E, et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. [J]. Eur J Pharmacol,2004, 496(1-3):189-195.
[174]林桂芸,谢生发,谢鸿,等.和厚朴酚抑菌作用的研究[J].成都大学学报(自然科学版),2003,22(2)：18-20.
[175]Wang JP, Ho TF, Chang LC, et al. Anti-inflammatory effect of magnolol, isolated from Magnolia officinalis, on A231872-induced pleurisy in mice[J]. J Pharm Pharmacol,1995,47(10):857-860.
[176]李杰萍,梁统,周克元.厚朴酚对趋化三肽激活的大鼠中性粒细胞功能的影响[J].中国药科大学学报,2003,34(3)：260-263.
[177]Xianhe B, Francesca C, Masuko U, et al. Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesisin Vitro and Tumor Growth in Vivo[J]. J Biol Chem,2003,278(37):35501-35507.
[178]Yang SE, Hsieh MT, Tsai TH, et al. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells[J]. Br J Pharmacol,2003, 138(1):193-201.
[179]Lin SY, Liu JD, Chang HC, et al. Magnololsuppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apotosis[J]. J Cell Biochem,2002,84(3):532-544.
[180]Kenji I, Teru H, Makoto H, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and independent apoptosis[J]. Blood,2005,106:1794-1800.
[181]Fong W, Tse A, Poon K, et al. Magnolol and honokiol enhance HL-60 humanl eukemia cell differentiation induced byl,25-dihydroxyvitamin D3 and retinoic acid[J]. Int J Biochem Cell Biol,2005,37(2):427-441.
[182]Syu WJ, Shen CC, Lu JJ, et al. Antimicrobial and cytotoxic activities of neolignans from Magnolia officinalis[J]. Chem Biodivers,2004, 1(3):530-537.
[183]Chiu JH, Ho CT, Wei YH, et al. In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury[J]. Life Sci,1997,61(19):1961-1971.
[184]Lee YM, Hsiao G, Chen HR, et al. Magnolol reduces myocardial ischemia/ reperfusion injury via neutrophil inhibition in rats[J]. Eur J Pharmacol,2001, 422(3):159-167.
[185]Huang CH, Hong CY, Tsai SK, et al. Intravenous pretreat ment with magnolol protects myocardium against stunning[J]. Planta Med,2000,66(6):516-520.
[186]Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis[J]. Thromb Res,1988,50(6):757-765.
[187]Zhang GQ, Chem SZ, Hao XM, et al. The protective effect of magnolol on cerebral ischemia[J]. Chin Pharmacol Bull,2003,19(9):1020-1023.
[188]Liou KT, Shen YC, Chen CF, et al. Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production [J]. Brain Res,2003,992(2):159-166.
[189]Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis[J]. Thromb Res,1988,50(6):757-765.
[190]Li B, Masukawa N, Yamaki M, et al. Four stilbenoids from Pleione bulbocodioides[J]. Phytochemistry,1998,48(2):327-331.
[191]U. Sankawa, E. Yutaka, M. Trutaka. Antitumor activity of shikonin and its derivatives [J]. Chemical and Pharmaceutical Bulletin.1977.25.2392-2395.
[192]吴振.紫草素诱导肿瘤细胞凋亡机制研究[D].沈阳药科大学,2004.
[193]Sasaki, K., Yoshizaki, F., Abe, H. The anti-Candida activity of shikon[J]. Yakugaku Zasshi,2000,120(6):587-589.
[194]佐佐木健郎.紫草成分的抗真菌活性及其对念珠菌性口腔疾患的改善作用[J].国外医学中医中药分册,2004,26(5)：310.
[195]Kaith, B. S., Kaith, N. S., Chauhan, N. S Anti-inflammatory effect of Arnebia euchroma root extracts in rats[J]. Journal of Ethnopharmacology,1996,55:77-80.
[196]王文杰,白金叶,刘大培,等.紫草素抗炎及对白三烯B4生物合成的抑制作用[J].药学学报,1994,29(3)：161-165.
[197]Singh B., Sharma, M. K., Meghwal, P. R., Sahu, P. M., and Singh S. Anti-inflammatory activity of shikonin derivatives from Arnebia hispidissima[J]. Phytomedicine,2003,10:375-380.
[198]刘燕,买尔旦·马合木提,尼加提·热合木.新疆紫草提取物对小鼠急性四氯化碳性肝损伤的保护作用[J].时珍国医国药,2006,17(9)：1676-1678.
[199]买尔旦·马合木提,刘燕,尼加提·热合木.新疆紫草提取物对D一氨基半乳糖致小鼠急性肝损伤的保护作用[J].中国中药杂志,2006,31(19)：1646-1649.
[200]Yamasaki K, Otake T, Mori H, Morimoto M, Ueba N, Kurokawa Y, Shiota K, Yuge T. Screening test of crude drug extract on anti-HIV activity[J]. Yakugaku Zasshi, 1993,113(11):818-24.
[201]江苏新医学院.中药大辞典[M],上海：上海人民出版社,1977,721-723.
[202]孙立彦,刘振亮,孙金霞,等.白茅根多糖对小鼠耐缺氧作用的影响[J].中国医院药学杂志,2008,28(2)：96-99.
[203]岳兴如,侯宗霞,刘萍,等.白茅根抗炎的药理作用[J].中国临床康复,2006,10(43)：85-87.
[204]付嘉,熊斌,白丰沛,等.白茅根对小鼠细胞免疫功能影响[J].黑龙江医药科学,2000,23(2)：17.
[205]焦坤,陈佩东,和颖颖,等.白茅根研究概况[J].江苏中医药,2008,40(1)：91-93.
[1]郭玉民,呼子奇.高脂血症的防治[J].中国水电医学,2009,1：42-43.
[2]韦侃侃,胡滨山,张莉蓉ABCG8 T400K基因多态性与高脂血症的关系[J].河南预防医学杂志,2009,20(4)：246.
[3]容春莉,彭应心,刘美霞,王秀萍,宋津晓.中国北方汉族人载脂蛋白E基因多态性与血脂代谢的关系[J].中国现代医学杂志.2008.18(5)：586.
[4]孙赞,李玲,马庆宏.载脂蛋白E基因多态性与血脂和冠状动脉粥样硬化性心脏病相关性的研究[J].辽宁医学杂志,2008,22(1)：7.
[5]张培珍,田野ApoB、ApoE基因多态性与血脂异常的关系及运动训练的影响.[J]体育科学,2006,26(10)：65.
[6]李溪,姚成立,宋梅,等.载脂蛋白A5基因56C>G多态性与血甘油三酯相关性的研究[J].宁夏医学杂志,2006,28(9)：643.
[7]赵水平,肖志杰,李全忠,等.ATP结合盒转运子A1基因R219K变异对血脂的影响[J].中华医学杂志,2004,84(17)：1421.
[8]唐和年,张总刚,杜宇奎.新疆汉族和维吾尔族健康人群VKORC1启动子区基因多态性研究[J].中国优生与遗传杂志.2007,15(3)：16.
[9]杨胜利,何秉贤,何作云,等.新疆维汉两民族冠心病患者载脂蛋白E基因多态性研究[J].中国微循环,2004,8(1)：21
[10]李涛,李南方,周玲.新疆哈萨克族人群中血脂水平与AT1R基因A1166C多态性的相关研究[J].心脑血管病防治,2007,7(1)：4
[11]苏蓉,于德水.高脂血症的危害及防治[J].疾病防控,2009,16(8)：128-129.[12]吕瑞娟,张运,陈玉国,等.他汀类药物治疗ALT升高的急性冠状动脉综合征的可行性研究[J].新医学,2006,37(6)：368-369.
[13]吴家恩.阿托伐他汀钙治疗高脂血症的疗效观察[J].医药世界,2009,11(8)：414.
[14]金志泽.辛伐他汀的降脂疗效及对颈动脉粥样硬化的影响[J].中国综合临床,2002,18(1)：44-45.
[15]尤丽吐孜·努尔,温切木·吾斯曼.不同剂量舒降之治疗肾病综合征合并高脂血症的疗效观察[J].中外医疗,2009,22：93.
[16]佟以东,李铁柱.不同剂量辛伐他汀治疗冠心病合并高血脂症的疗效和安全性观察[J].黑龙江医学,2006,30(4)：278-279.
[17]阚光树,何道荣.氟伐他汀治疗高脂血症患者的疗效观察[J].华西医学,2009,24(1)：118-119.
[18]张利璧,冯玉宝.血脂异常治疗新进展[J].中国误诊学杂志,2005, 5(15)：2824-2825.
[19]唐丽洁,范昱,朱有华.非诺贝特对肾移植后高脂血症环孢素浓度影响[].医药论坛杂志,2008,29(8)：1-2.
[20]赵进,韦建瑞,吴同果.烟酸缓释片治疗混合性高脂血症的疗效[J].广东医学,2008,29(8)：1402-1403.
[21]JEFFREY T, AL IA, ALAW IA, et a.1 High-density Lipoprotein Cholesterol-Raising Strategies [J]. J Card Phann aco 1,2006,47(2):196.
[22]GANJI SH, KAMANNA V S, KASHYAP M L. N iacin and cholestero:l role in card iovascu lar d isease[J]. Jnu tr Bioch en,2003,14(6):298-305.
[23]汪艺,郑峰,张小平.阿昔莫司联合普伐他汀治疗老年混合型高脂血症的疗效与安全性[J].中国老年保健医学,2008,6(4)：23-25.
[24]Guyton JR, Buy HE. Safety considerations with Niacin therapy[J]. Am J Cardiol, 2007,99(6A):22C-31C.
[25]Taylor A J, Sullenberger LE, Lee H J, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol(ARBITER)2.A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins[J]. Circulation,2004,110:3512-3517.
[26]李卫群,陈华萍.辛伐他汀联合藻酸双脂钠治疗高胆固醇血症及高脂血症的临床观察[J].广东医学院学报,2005,23(2)：187-188.
[27]宫旭海,杨彩云,赵春环,等.甘糖酯、立普妥对脑梗塞合并高脂血症患者降脂疗效对比[J].中国实验诊断学,2008,12(12)：1599-1600.
[28]徐庆,刘英华,王觐,等.中长链脂肪酸食用油对高甘油三酯血症患者脂代谢的影响[J].军医进修学院学报,2009,30(4)：511.
[29]张红岩.多烯酸乙酯康胶丸治疗高脂血症30例调查分析[J].中国现代药物应用,2008,2(16)：34-35.
[30]杨彦平.弹性酶治疗高脂血症伴非酒精性脂肪肝的临床观察[J].中国现代药物应用,2009,3(3)：77-78.
[31]王云,柯元南,王嘉莉,等.多廿烷醇与普伐他汀治疗高脂血症的疗效和安全性[J].中国新药与临床杂志,2008,27(2)：124-127.
[32]李燕华,安英娣.谷维素调脂作用临床观察[J].临床荟瘁,2003,18(5)：274.
[33]何解生.谷维素的临床新用途[J].实用药物与临床,2006,9(2)：110-111.
[34]钟湘,杨文君,吴禹.谷维素合并维生素E治疗高脂血症的临床观察[J].第三军医大学学报,2007,29(11)：1128.
[35]A ccinn iR, Ros ina M, Bam on ti F, et al. E ffects of com bined d ietary supplem en tat ion on oxidat ive and in flamm atory statu s in dyslipidem icsub jects[J]. Nu trM etab Card iovasc Dis,2006,16(2):121-127.
[36]饶刚,唐学文.云芝胞内多糖治疗高血脂症作用的临床观察[J].重庆医学,2007,36(13)：1306-1307.
[37]Sirtori CR, Calabresi L, Ferrara S, et al. L2carnitine reducesp lasma lipop rotein(a)levels in patientswith hyper Lp(a)[J]. NutrMetab Cardiovasc Dis,2000, 10(5):247-251.
[38]Argani H, RahbaninoubarM, Ghorbanihagjo A, et al. Effect of Lcarnitine on the serum lipoproteins and HDL-C subclasses in hemodialysis patients [J]. Nephron Clin Pract,2005,101(4):174-179.
[39]Gunes B, Yalcin SS, Kalkanoglu HS, et al. The effect of oral Lcarnitine supp lementation on the lipid profiles of hyperlipideamic children[J]. Acta Paediatr,2005, 94(6):711-716.
[40]许宏安,施陈刚.辛伐他汀非诺贝特交替治疗混合性高脂血症安全性、有效性观察[J].浙江临床医学,2006,8(1)：38.
[41]孙晓红,彭晓玲,朱蕾.小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症临床疗效及安全性[J].中华高血压杂志,2007,15(5)：387.
[42]AronowW S. Pharmacologic therapy of lipid disorders in the elderly [J]. Arm J Geriatr Cariol,2002,11(4):247-256
[43]乔淑章,陈莉,康文巧,等.半导体激光穴位照射治疗高脂血症60例[J].河北中医,2005,27(3)：208.
[44]关敏.磁极化血液净化冷凝离子吸附治疗高脂血症、高粘血症[J].中国水电医学,2005,1：9-10.
[45]陆明晰,胡卫民,冯剑,等.二重血浆分离治疗高脂血症及急性高脂血症性胰腺炎[J].全科医学临床与教育,2007,5(5)：372-374.
[46]周丽萍,朱彩侠.高压臭氧联合调脂汤治疗高脂血症98例[J].陕西中医,2009,30(6)：680-681.
[47]王堂明,邱波.血液灌流治疗高脂血症的临床研究[J].透析与人工器官,2006,17(4)：28-29.
[48]赵奕华,邢昌赢,邹元国,等.中国血液净化,2008,7(1)：19-20.
[49]冉君花,刘辉.营养联合运动治疗对高脂血症患者血脂的影响[J].中国疗养医学,2009,18(2)：102-103.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |